Previously, using recombinant human progastrin-releasing peptide (Pr0GRP)(31-98), we developed a AlA for Pr0GRP (31 -98) and demonstrated that the determination of serum Pr0GRP(31 -98) was a reliable marker for smallcell lung carcinoma (SCLC) (Miyake et al., Cancer Res 1994;54:2136-40).
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Results

Analytical Variables
Antigens. Recombinant ProGRP(31-98) was expressed in large quantities as a TrpE fusion protein in E. coli (Fig. 1B) and was purified from the cells carry- and a mixed coating of 2B10 and 3G2 in equal quantities on the plate produced in the lowest detection limit with HRP-conjugated rabbit pAb (data not shown). Therefore, we selected 2B10 and 3G2 for immobilized antibodies.
ELISA for ProGRP(31-98).
A sandwich ELISA for ProGRP(31-98) was established by using the optimized reaction components, concentrations, and assay conditions. The calibration curve was linear up to 1000 ng/L on a log-log scale (Fig. 2) To analyze the immunoreactivity measured by this ELISA in biological fluids, we examined the gel-filtration study of extracts of SCLC tissue and serum from a SCLC patient (Fig. 3) . The total amount ofProGRP(31-98) was measured in each fraction. This ELISA system recognized one major peak in the tissue sample as well as in the serum sample, each peak eluting at a position slightly in front of cytochrome c. The molecular size of this peak seemed to be greater than that of Pro-GRP(3 1-98).
We We also demonstrated that SCLC cells produce equimolar amounts of GRP(1-27) and Pro-GRP(31-98), although the latter was more stable in the blood than the former (13).
We succeeded in generating four mouse mAbs and a rabbit polyclonal antiserum.
Results from the competitive-binding ELISA suggested that our mAbs recognized mainly two epitopes. We assumed that the avidity between ProGRP(31-98) and the immobilized antibodies on solid phase became stronger when we immobilized two mAbs that recognized different epitopes on the ProGRP (31-98) molecule. On the basis of the combination of these two mAbs and HRP-conjugated rabbit pAb, we developed a sensitive and specific ELISA for ProGRP(31-98), using various optimized reaction variables.
With this ELISA, recombinant Pro-GRP(31-98) could be used as a calibrator because both recombinant and native ProGRP(31-98) in serum had the same reactivity (Fig. 2) , and because the analytical recovery of various concentrations of recombinant Pro-GRP(31-98) added to three sera was 91.5% to 108.7% (data not shown).
Gel-filtration studies revealed that this ELISA system recognized one major peak (eluting slightly ahead of cytochrome c) in tissue extracts and serum obtained from a SCLC patient (Fig. 3) . The retention time of the peak by this ELISA was equal to that by RIA (13 Interference.
We assessed the influence of anticoagulants and blood elements in serum on ELISA results. The anticoagulants EDTA (<20 g/L), heparin (<0.2 g/L), NaF (<2.0 g/L), sodium oxalate (<0.6 g/L), and sodium citrate (<100 g/L) showed no interference with the assay.
Assessment
of the influence of hemoglobin (<4.9 g/L), bilirubin (<0.19 g/L), lipemia (turbidity, with lipids up to 16.5 g/L), and rheumatoid factor (<400 kJU/L) also showed no interference in this assay (data not shown).
Serum ProGRP(31-98) Distribution in Healthy Subjects and Patients
The distribution of the serum ProGRP(31-98) concentrations in healthy subjects is shown in Fig. 4 . The concentrations in these subjects ranged from 1.9 to 74.6 ng/L. The distribution pattern was gaussian after logarithmic transformation. Estimated after this transformation, the mean + 1.96 SD was 27.0 ng/L; the mean + 3 SD, which we tentatively set as the cutoff value of this assay, showed that the rabbit antiserum against ProGRP(31-52) recognized the 14-kDa molecule in extracts derived from SCLC cell lines. This latter result almost corresponds with our results. However, the 27-28-kDa molecular form was not recognized by our ELISA system. In the ProGRP(31-98) RIA reported previously, the minimum detectable amount in serum was 10 pmol/L (78 ngfL), which was insufficient to detect serum Pro-GRP(31-98) in healthy subjects. Moreover, this RIA system took 5 days to obtain the result and, of course, required radiolabeled materials
In contrast, the ELISA we developed had a minimum The immunoreactivity of ProGRP(31-98) detected in serum of healthy subjects was specifically inhibited by two anti-ProGRP(31-98) mAbs. Therefore, we postulate that serum ProGRP(3 1-98) concentrations in normal subjects can be evaluated in terms of various criteria, e.g., subject's age, sex, and history of smoking.
In tumor marker studies, the establishment of a cutoff value is very important for evaluating a truepositive rate in cancer patients or a false-positive rate in normal subjects or patients with benign diseases. We tentatively set the cutoff value as the mean + 3 SD (45.1 ng/L) of the distribution pattern of serum Pro-GRP in the healthy subjects tested. According to that criterion, the frequency of above-normal serum concentrations of ProGRP(3 1-98) in healthy subjects or patients with nonmalignant pulmonary diseases or in non-SCLC patients was almost equal to that determined with our RIA, i.e., 0% to 5% (Table 1) ; however, the number of cases examined in this study is not large. In contrast, -72% of SCLC patients had above-normal 
